Campaign Finance$750 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Salix Pharmaceuticals
Names of Lobbyists
Most Frequently Disclosed Lobbying Issues
- Health Issues
RegulationsMentioned in 7 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Salix Pharmaceuticals" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for Salix Pharmaceuticals
- Toggle 2 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
- Toggle 2 FDA To Apply FDA's Previously Announced Bioequivalence Standards for Delayed-Release Mesalamine 400 mg Tablets as an Abbreviated New Drug Application - CLOSED 2011
- Toggle 1 FDA Draft Guidance for Industry on Heparin for Drug and Medical Device Use; Monitoring Crude Heparin for Quality 2012
- Toggle 1 CMS Hospital Outpatient Prospective and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Electronic Reporting Pilot; Inpatient Rehabilitation Facilities Quality Reporting Program; Quality Improvement Organization Regulations 2012
- Toggle 1 FDA Patent Term Extension Application for SUPREP™ Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate), US Patent No. 6,946,149 2011
- Toggle 1 FDA Request the Clarification of Existing Criteria and Establish Additional Criteria for how to Demonstrate Bioequivalence for Mesalamine Delayed-Release Tablets 2012
- Toggle 1 FDA Refrain From Approving Any Abbreviated New Drug Application Referencing Copaxone® (Glatiramer Acetate Injection) Unless and Until The Conditions Specified in This Petition are Satisfied 2012